Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

High frequency of low-count monoclonal B-cell lymphocytosis in hospitalized COVID-19 patients

  • Oliva-Ariza, Guillermo
  • Fuentes-Herrero, Blanca
  • Carbonell, Cristina
  • Lécrevisse, Quentin
  • Pérez-Pons, Alba
  • Torres-Valle, Alba
  • Pozo, Julio
  • Martín-Oterino, José Ángel
  • González-López, Óscar
  • López-Bernús, Amparo
  • Bernal-Ribes, Marta
  • Belhassen-García, Moncef
  • Pérez-Escurza, Oihane
  • Pérez-Andrés, Martin
  • Vázquez-López, Lourdes
  • Hernández-Pérez, Guillermo
  • García Palomo, Francisco Javier
  • Leoz, Pilar
  • Costa-Alba, Pilar
  • Pérez-Losada, Elena
  • Yeguas Bermejo, Ana
  • Santos Sánchez, Miryam
  • García-Blázquez, Marta
  • Morán-Plata, F. Javier
  • Damasceno, Daniela
  • Botafogo, Vitor
  • Muñoz-García, Noemí
  • Fluxá, Rafael
  • Contreras-Sanfeliciano, Teresa
  • Almeida, Julia
  • Marcos, Miguel
  • Orfao, Alberto
Low-count monoclonal B-cell lymphocytosis (MBLlo, <500 clonal B-cells/μL) is a highly prevalent condition in the general population (4% to 16% of otherwise healthy adults), which increases significantly with age.1-7 In most cases, clonal B-cells share phenotypic and cytogenetic features with chronic lymphocytic leukemia (CLL), but only a small fraction (≈1.8%) progresses to high-count MBL (MBLhi; ≥500 and <5000 clonal B-cells/μL)3 in the medium-term.8 However, previous reports showed that MBLlo subjects had an increased risk of severe infections in association with a (predominantly) secondary antibody deficiency,8-10 suggesting that MBLlo might be a risk marker for developing more severe infections., This work was supported by the Instituto de Salud Carlos III (Ministerio de Ciencia e Innovación, Madrid, Spain, and FONDOS FEDER (a way to build Europe) grants CB16/12/00400 (CIBERONC), COV20/00386, and PI17/00399; the Consejería de Educación and the Gerencia Regional de Salud, Consejería de Sanidad from Junta de Castilla y León (Valladolid, Spain) grants SA109P20 and GRS-COVID-33/A/20; the European Regional Development Fund (INTERREG POCTEP Spain-Portugal) grant 0639-IDIAL-NET-3-3; and the CRUK (United Kingdom), Fundación AECC (Spain), and Associazione Italiana per la Ricerca Sul Cancro (Italy) “Early Cancer Research Initiative Network on MBL (ECRINM3)” ACCELERATOR award. G.O.-A. is supported by a grant from the Consejería de Educación, Junta de Castilla y León (Valladolid, Spain); B.F.-H. was supported by grant 0639-IDIAL-NET-3-3., Peer reviewed